Online version of the 2013-14 Department of Health Annual Report

Outcome 2: Access to Pharmaceutical Services

Access to cost-effective medicines, including through the Pharmaceutical Benefits Scheme and related subsidies, and assistance for medication management through industry partnerships

Page last updated: 17 July 2019

Major Achievements

  • Provided patients with continued access to affordable and high quality medicines and pharmaceutical services. This was achieved through subsidising medicines through the Pharmaceutical Benefits Scheme (PBS) and Life Saving Drugs Programme (LSDP) and by supporting the provision of aids and appliances through programmes such as the National Diabetes Services Scheme and the Stoma Appliance Scheme.
  • Implemented the Government’s commitment to allow the Minister for Health to approve listings for the PBS that are estimated to cost $20 million or less in each of the forward estimates years. This is providing faster listing times for some medicines and improved patient access to important new treatments.
  • 311 new and amended PBS listings (including 40 price increases), at an overall cost of $596.8 million over five years, to treat a range of illnesses, were approved.
  • Completed the Review of Funding Arrangements for Chemotherapy Services and implemented the new arrangements to ensure continued access to chemotherapy medicines.
  • Streamlined the operation of price disclosure arrangements to allow price reductions on medicines to occur sooner and more frequently after medicines become subject to market competition. This is expected to save the Government $835 million, with some patients paying up to $11.76 less per script from 1 October 2014. These savings are already factored into the forward estimates and are part of over $9 billion in savings estimated to be achieved by 2016-17 since the inception of PBS pricing reforms by the Howard Government in 2007.
  • Implemented sustainable arrangements for programmes and services funded under the Fifth Community Pharmacy Agreement. This ensured that more than 300,000 medication management services were delivered to consumers at risk of medication misadventure in 2013-14.

Challenges

  • Ensuring the long term sustainability of the PBS.

Looking Ahead

In 2014-15, the Department will continue work with the pharmaceutical industry to enable the listing of cost-effective innovative medicines on the PBS. In addition, the Department will manage the reviews of the LSDP which provides Australians with very rare conditions access to much-needed, expensive medicines and Authority Required PBS listings which will reduce regulatory burden on prescribers and improve patient care. The Department will further reduce red tape for medical practitioners by introducing the supply and claiming of PBS medicines from medication charts in all public and private hospitals, aligning with arrangements being implemented in Residential Aged Care Facilities. This initiative will deliver medication safety benefits to patients, improving the quality use of medicines and health outcomes through reductions in transcription errors.

Programmes Contributing to Outcome 2

  • Programme 2.1: Community pharmacy and pharmaceutical awareness
  • Programme 2.2: Pharmaceuticals and pharmaceutical services
  • Programme 2.3: Targeted assistance – pharmaceuticals
  • Programme 2.4: Targeted assistance – aids and appliances

Divisions Contributing to Outcome 2

In 2013-14, Outcome 2 was the responsibility of Pharmaceutical Benefits Division.

Outcome Strategy

Outcome 2 aims to provide reliable, timely and affordable access to cost-effective, sustainable and high quality pharmaceutical medicines and services. In 2013-14 the Department worked to achieve this Outcome by managing initiatives under the programmes outlined below.

Programme 2.1: Community pharmacy and pharmaceutical awareness

Programme 2.1 aims to support timely access to medicines and pharmacy services through the Fifth Community Pharmacy Agreement (the Fifth Agreement). Funding is provided to support a range of services that improve medication management for people at risk of adverse medication events, and through this, reduce the risk of hospitalisation. This programme also supports quality use of medicines for Aboriginal and Torres Strait Islander peoples through education and targeted support for health professionals.

Support timely access to medicines and pharmacy services through the Fifth Community Pharmacy Agreement

The Fifth Agreement provides $663.4 million over five years (2010-2015) for a range of services and programmes that seek to improve patient outcomes, through optimising their medication management and improving the quality use of medicines. These services aim to reduce rates of medication misadventure and potential hospitalisation due to medicines-related adverse events in the Australian community. An evaluation of the effectiveness of Fifth Agreement programmes and services will be undertaken in accordance with the Fifth Agreement Evaluation Framework.

From 1 March 2014, the Pharmacy Guild of Australia assumed responsibility for administering a number of programmes and services under the Fifth Agreement.

Qualitative Deliverable
Phased roll out of measure: Electronic Recording and Reporting of Controlled Drugs
2013-14 Reference Point
Continue measure phase in, for completion during the first half of 2013-14, including working with jurisdictions to facilitate the delivery of this measure32
Result
Met
The Electronic Recording and Reporting of Controlled Drugs system is available for use by State and Territory Governments.
Qualitative Deliverable
Phased roll out of measure: Supply and PBS Claiming from a Medication Chart in Residential Aged Care Facilities
2013-14 Reference Point
Continue measure phase in, for completion during 2013-14, including evaluation of the National Residential Medication Chart in pilot sites prior to consideration of a national rollout
Result
Met
Supply and claiming from a medication chart will improve medication safety for residents of aged care homes. It will also streamline access by enabling pharmacists to supply and claim PBS medicines from orders written on a standardised medication chart, instead of requiring an additional prescription.
Qualitative Deliverable
Phased roll out of measure: Continued Dispensing of PBS Medicines in Defined Circumstances
2013-14 Reference Point
Continue measure phase in, for completion during 2013-14, dependent on state and territory enabling legislation being introduced to facilitate the delivery of this measure
Result
Met
Quantitative Deliverable
Number of medication management services provided under the Fifth Agreement
2013-14 Target
64,500
2013-14 Actual
108,246
Result
Met
The number of medication management services provided under the Fifth Agreement: 2010-11 61,353 medication management services, 2011-12 74,346 medication management services, 2012-13 115,894 medication management services. In 2013-14, 108,246 medication management services were funded through the Home Medicines Review (HMR) programme, under the Fifth Agreement.
In March 2014, a number of changes to medication management services occurred, in order to sustain the programmes funded under the Fifth Agreement. This included placing a limit on the number of HMR MedsCheck and Diabetes MedsCheck that can be performed in a calendar month. Limits were also placed on the timeframes for repeat reviews and referrals, to ensure timely services were delivered to the community.
Quantitative KPI
Percentage of rural community pharmacies accessing targeted rural programmes to support the sustainability of community pharmacy in rural and remote Australia
2013-14 Target
75%
2013-14 Actual
86%
Result
Met
Quantitative KPI – Percentage of rural…
The percentage of rural community pharmacies accessing targeted rural programmes to support the sustainability of community pharmacy in rural and remote Australia: 2010-11 83 per cent, 2011-12 89 per cent, 2012-13 82 per cent. In 2013-14, 86% of rural community pharmacies (755 of 877) accessed one or more elements of targeted rural programmes.
Quantitative KPI
Percentage of community pharmacies participating in the Pharmacy Practice Incentives Programme
2013-14 Target
90%
2013-14 Actual
93%
Result
Met
Quantitative KPI – Percentage of community…
The percentage of community pharmacies participating in the Pharmacy Practice Incentives Programme: 2011-12 75 per cent, 2012-13 82 per cent.In 2013-14, 93% of community pharmacies participated in one or more components of the Pharmacy Practice Incentives Programme.

Programme 2.2: Pharmaceuticals and pharmaceutical services

Programme 2.2 aims to provide access to clinically-effective, innovative, cost-effective, medicines to all Australians, and ensure the sustainability of the PBS.

List clinically-effective, innovative, cost-effective medicines on the PBS

The PBS aims to provide Australians with timely access to a wide range of affordable and cost-effective medicines. In 2013-14, the PBS subsidised around 770 medicines available in more than 2,040 forms and marketed as more than 4,780 differently branded items. In 2013-14, the PBS cost $9.15 billion, 1.7 per cent growth in the programme since 2012-13.

Quantitative KPI
Number of prescriptions subsidised through the PBS
2013-14 Target
206m
2013-14 Actual
210m
Result
Met
Quantitative KPI – Number of prescriptions…
The number of prescriptions subsidised through the PBS: 2010-11 188 million PBS prescriptions, 2011-12 194.5 million PBS prescriptions, 2012-13 197 million PBS prescriptions.In 2013-14, 210 million PBS prescriptions were subsidised against an estimate of 206 million, representing approximately 9 prescriptions per person. This compares to 197 million prescriptions or 8.6 per person in 2012-13. The collection of under co-payment prescription data for the PBS and the Repatriation PBS (RPBS) commenced on 1 April 2012. Information on the number of scripts and the medicines supplied annually through these prescriptions is available at http://www.pbs.gov.au/info/news/2011/07/pbs-collection-of-under-copayment-data
Qualitative Deliverable
The Pharmaceutical Benefits Advisory Committee meets at least three times a year and provides recommendations to the Minister on new listings for the PBS
2013-14 Reference Point
The PBAC recommendations for listing on the PBS are based on the clinical effectiveness and cost-effectiveness of new medicines, and provided in a timely manner
Result
Met
The PBAC met on four occasions during 2013-14. The PBAC recommendations were provided to product sponsors and the Minister for Health, and made publicly available in timeframes consistent with long standing arrangements agreed with the pharmaceutical industry. All PBAC assessments are based on the clinical and cost-effectiveness of the medicine.
Quantitative Deliverable
Percentage of the community’s (public) comments included for consideration at each Pharmaceutical Benefits Advisory Committee meeting
2013-14 Target
100%
2013-14 Actual
100%
Result
Met
In 2013-14, there were 2,712 consumer submissions on matters before the PBAC, compared with 792 received in 2012-13 and 942 in 2011-12. Consumer comments on medicines under consideration by the PBAC are summarised, provided to the product sponsor, and taken into account by the PBAC in its decision making process.
Qualitative Deliverable
Price negotiations with sponsors and conditions for listing finalised, and quality and availability checks undertaken for new PBS listings
2013-14 Reference Point
All negotiations and listing activity completed in a timely manner
Result
Met
The negotiations with product sponsors and listing requirements for new and amended listings of medicines on the PBS were completed in a timely manner.
On 1 April 2014, in line with Government’s deregulation agenda, the Department implemented a new streamlined process to reduce the time taken to list medicines on the PBS and improve access to medicines. A key component of this measure was the cessation of the operations of the Pharmaceutical Benefits Pricing Authority. The process allows important new medicines to be listed on the PBS at least four weeks earlier than previously. Sponsors benefit from having additional time in which to finalise pricing submissions following a positive PBAC recommendation. First reporting on the benefits achieved from this change will occur in 2014-15.
The price of each drug listed on the PBS, by anatomical therapeutic chemical group, continued to be reviewed annually.
Quantitative KPI
Revenue received from the cost recovery of the PBS listing process
2013-14 Target
$10.0m
2013-14 Actual
$9.9m
Result
Met
The revenue received from the cost recovery of the PBS listing process: 2010-11 $7.8 million, 2011-12 $6.8 million, 2012-13 $9.2 million.PBS cost recovery arrangements for the listing of new medicines or vaccines, or to vary the listing of existing products, were introduced from 1 January 2010. Revenue depends on factors outside the control of the Department, such as the type and number of submissions, and the number of waivers and exemptions applicable. On average 1 in 3 submissions considered by the PBAC are not charged fees.

Increase the sustainability of the PBS

The Government needs to ensure that the PBS is managed in a fiscally responsible and sustainable way. PBS policies need to strike a balance between providing access to new, innovative and often prohibitively expensive medicines, but at a cost patients and the community, including taxpayers, can afford.

Implemented the Government’s commitment to allow the Minister for Health to approve listings for the PBS that are estimated to cost $20 million or less in each of the forward estimates years. Only proposals that will cost more than $20 million in any one year will require approval by the Cabinet. This is providing faster listing times for some medicines and improved patient access to important new treatments.

In 2013-14, the Government approved 311 new and amended PBS listings (including 40 price increases), at an overall cost of $596.8 million over five years, to treat a range of illnesses. This equates to an average of 26 new and amended listings per month.

This includes the listing of everolimus (Afinitor®), from 1 June 2014 for the treatment of advanced breast cancer, at an overall cost of $163.2 million over five years. The listing for everolimus provides an affordable option for up to 1,400 patients who have not responded to other treatments, which would normally cost these patients as much as $38,000 per year, without the PBS subsidy.

In addition, from 1 May 2014 a new treatment option for Australians living with Human Immunodeficiency Virus (HIV) was listed on the PBS. More than 1,500 patients living with HIV will benefit from a fixed dose combination of tenofovir disoproxil fumarate + emtricitabine + elvitegravir + cobicistat (sold as Stribild®), with a patient on this particular combination normally paying more than $24,000 per year without the PBS subsidy.

Table 2.1: High cost medicines listed in 2013-14
MEDICINE
INDICATION
LISTING DATE
ESTIMATED NUMBER OF PATIENTS PER ANNUM
ESTIMATED EXPENDITURE – 5 YEARS (FISCAL) ($m)
Abiraterone (Zytiga®)
Castration resistant metastatic prostate cancer
August 2013
1,000
57.9
Ipilimumab (Yervoy®)
Unresectable malignant melanoma
August 2013
1,520
669.5
Rivaroxaban (Xarelto®)
Atrial fibrillation
August 2013
120,000
667.7
Dabrafenib (Tafinlar®)
Malignant melanoma
December 2013
850
155.9
Everolimus (Afinitor®)
Advanced breast cancer
June 2014
1,400
163.2
Ferric carboxymaltose (Ferinject®)
Iron deficiency anaemia
June 2014
Approximately 88,000 infusions per year
93.0

The Department has also implemented Simplified Price Disclosure, which will continue to assist the ongoing sustainability of the PBS, in addition to the existing price disclosure arrangements, which combined will return over $9 billion to the programme.

Quantitative KPI
Estimated savings to Government from further PBS Reforms33
2013-14 Target
$1,477.7m
2013-14 Actual
$1,309.3m
Result
Substantially met
PBS Reforms, including Price Disclosure Programme, saved the Government $1,309.3 million in 2013-14. This includes savings from all rounds of Price Disclosure prior to 30 June 2014; savings from the 2% and 5% reductions on 1 February 2011 in the prices of all medicines listed on the F2A and F2(T) formularies respectively on 11 October 2010; and savings from the 1 February 2011 increase from 12.5% to 16% in the statutory price reduction applied to all medicines when their first generic competitor lists on the PBS. This is lower than the forecast of $1,477.7 million, primarily due to a number of the affected medicines experiencing lower script growth than originally forecast.

Post-market reviews

Post-market monitoring has been designed to improve patient safety, and quality use of medicines through a coordinated governance framework that draws on existing programmes and data sets to monitor the actual use of medicines in clinical practice. This will allow the earlier identification of quality use of medicines issues including adverse events, improve prescribing and dispensing (through an enhanced ability to target education and support) and improve the sustainability of the PBS in the longer term through the integration of routine assessment of medicines use in the real world, including cost-effectiveness reviews for subsidised medicines.

In 2013-14, the Department completed the post-market review of PBS medicines used to treat asthma in children report and the first report of the review of products used for the management of diabetes. The final parts of the diabetes review are nearing completion. The post-market reviews of the LSDP and the Authority Required PBS Listings have been announced and are under way.

Qualitative Deliverable
Undertake reviews of medicines in use, focusing on the appropriate and quality use of medicines
2013-14 Reference Point
Complete two reviews in 2013-14: medicines used to treat asthma in children and medicines and products used to manage diabetes
Result
Substantially met
The final report on asthma in children was completed in June 2014 and considered by PBAC in July 2014. The first report of the diabetes review covering the use of blood glucose test strips was completed in 2013-14. A draft second report on the use of insulin pumps was released for public consultation in early July 2014, while the third report relating to the use of medicines for the treatment of diabetes is nearing completion.

Quality use of medicines

The Department continued to apply the National Medicines Policy to improve the quality use of medicines in the community, including considering issues such as antimicrobial resistance and health literacy.

The National Prescribing Service MedicineWise worked with health professionals and consumers to provide information on key areas such as achieving good practice with anticoagulants, promoting safe use of medicines in older people, asthma control and managing fatigue. Additional information is available in Outcome 10 (Programme 10.5).

Increased funding for chemotherapy services

In 2013-14 the Department undertook a Review of Funding Arrangements for Chemotherapy Services (the Review). The scope of the Review was broad and a range of stakeholders involved in the provision of chemotherapy were consulted. The Review considered all cost elements of the supply chain – compounding, preparation, dispensing and administration. Following consideration of the Review, the Government provided more than $82 million in additional funding over 18 months to ensure more than 150,000 cancer patients could access chemotherapy infusions dispensed under the PBS ‘Efficient Funding of Chemotherapy’ schedule. This additional funding provides certainty to chemotherapy patients and their families so that they will continue to have timely access to safe and effective treatment, whilst supporting the viability of community and hospital pharmacies providing chemotherapy infusions.

In 2014-15, the Department will work with the Australian Commission on Safety and Quality in Health Care to include the supply and claiming of PBS medicines from medication charts in all public and private hospitals, while the Department will undertake a Post-market Review of all PBS authority required medicines. Both of these initiatives have flowed from the outcomes of the Review and are expected to reduce regulatory burden for health professional and prescribers by removing unnecessary red tape.

Programme 2.3: Targeted assistance – pharmaceuticals

Programme 2.3 aims to improve access to new and existing medicines for patients with life threatening conditions.

Improve access to new and existing medicines for patients with
life threatening conditions

The LSDP provides patients with financial assistance to access expensive and life saving drugs not available on the PBS. In 2013-14, through the LSDP, the Government provided 257 eligible patients with access to ten fully subsidised medicines to treat seven very rare life threatening medical conditions.

The medicines that were subsidised included: imiglucerase (Cerezyme®), velaglucerase (VPRIV®) and miglustat (Zavesca®) for Type I Gaucher disease; agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®) for Fabry disease; laronidase (Aldurazyme®) for Mucopolysaccharidosis (MPS) Type I disease; idursulfase (Elaprase®) for MPS Type II disease; galsulfase (Naglazyme®) for MPS Type VI disease; alglucosidase alfa (Myozyme®) for infantile-onset Pompe disease; and eculizumab (Soliris®) for Paroxysmal Nocturnal Haemoglobinuria.

On 9 April 2014, it was announced that a review of the LSDP (LSDP Review) would be conducted as part of the Government’s post-market reviews programme. The LSDP Review, to be conducted by health experts, consumer representatives and an ethics advocate, is expected to be completed within 12 months.

The Government also announced that, from 1 May 2014, the five Disease Advisory Committees (DACs) would no longer be used to provide recommendations to the Department about the initial and continued eligibility of individual patients to receive subsidised treatment through the LSDP. Ceasing the DACs enables former committee members who are clinical experts in the relevant disease areas to participate fully in the post-market review of the LSDP and to freely advocate on behalf of their patients. Instead, access will be through existing Complex Authority Required arrangements.

The Department will access individual medical specialists with clinical expertise in the relevant disease areas as needed. However this need is expected to be minimal, given that treating physicians with relevant specialist registration routinely use clinical knowledge and experience to make decisions about the treatment and management of individual patients, or seek advice from other clinical experts in the relevant disease areas, in order to provide optimal care to patients.

In 2013-14, the Department continued to work with industry to finalise Deeds of Agreement for terms of supply for all medicines supplied through the LSDP, with risk share arrangements to effectively manage expenditure.

Qualitative Deliverable
Review programme guidelines to ensure they remain current and relevant
2013-14 Reference Point
Programme guidelines reviewed within agreed timeframes
Result
Met
All LSDP guidelines were reviewed to update information on administrative processes following the announcement about the commencement of the LSDP Review and the cessation of the five DACs.
Quantitative Deliverable
Number of patients assisted through the Life Saving Drugs Programme
2013-14 Target
245
2013-14 Actual
257
Result
Met
The number of patients assisted through the Life Saving Drugs Programme: 2010-11 210 patients, 2011-12 215 patients, 2012-13 228 patients.Through the Department, the Government provided a total of 257 patients with access to fully subsidised medicines for the treatment of their very rare life threatening medical conditions. Twelve more patients than anticipated were provided with assistance due to the demand driven nature of the programme.
Quantitative KPI
Percentage of eligible patients with access to fully subsidised medicines through the Life Saving Drugs Programme
2013-14 Target
100%
2013-14 Actual
100%
Result
Met
All eligible patients were provided with access to fully subsidised medicines for the treatment of their very rare life threatening medical conditions.
Qualitative KPI
Eligible patients have timely access to the Life Saving Drugs Programme
2013-14 Reference Point
Patient applications are processed within 30 calendar days of receipt
Result
Met
All applications were processed within 30 calendar days of receipt of the complete data package to support the application.

Programme 2.4: Targeted assistance – aids and appliances

Programme 2.4 provides access to necessary products and services to support people of all ages with Type 1, Type 2, gestational and other diabetes to effectively manage their condition. The programme also provides specific funding to allow children under 18 years of age to access insulin pump therapy which may otherwise not be affordable to their families. In addition programme 2.4 also assists people with stomas to access fully subsidised stoma-related products, and supports access to clinically appropriate dressings to improve the quality of life for people with Epidermolysis Bullosa.

Provide support for people with diabetes

The National Diabetes Service Scheme (NDSS) provides access to a range of products including blood glucose test strips and insulin pump consumables to more than one million people with diabetes. The NDSS is managed by Diabetes Australia on behalf of the Department, and represents an investment of $1 billion over the life of the current Agreement, which commenced on 1 July 2011 and will end on 30 June 2016.

Quantitative Deliverable
Number of people with diabetes receiving benefit from the NDSS
2013-14 Target
1,280,000
2013-14 Actual
1,133,412
Result
Substantially Met
Quantitative Deliverable – Number of people with diabetes The number of people with diabetes receiving benefit from the National Diabetes Service Scheme: 2011-12 1,037,621 people, 2012-13 1,086,860 people.The NDSS is a demand-driven programme. In 2013-14, the number of registrants under the NDSS was less than forecast, with 1,133,412 people with Type 1, Type 2 and gestational diabetes receiving benefit from the NDSS. However, there were also a further 59,706 people registered on the post gestational diabetes register who were also eligible to receive services from the NDSS. Further communication and marketing activity is planned for 2014-15 to increase awareness of the NDSS and the benefit it can offer to people with diabetes in supporting the self-management of their condition.
Qualitative Deliverable
Provide access to insulin pumps and associated consumables for children under 18 years of age with type 1 diabetes
2013-14 Reference Point
Work with the scheme administrator to ensure efficient insulin pump subsidies are provided
Result
Met
In 2013-14, the programme provided access to insulin pump therapy in accordance with the guidelines and available funding for the programme. The JDRF continued to undertake promotional and marketing activity to ensure families of children with Type 1 diabetes could apply for a subsidy where otherwise they may not have been able to receive this therapy.
Quantitative Deliverable
Number of people under 18 years of age with type 1 diabetes receiving a subsidised insulin pump
2013-14 Target
204
2013-14 Actual
204
Result
Met
Quantitative Deliverable – Number of people under 18 years The number of people under 18 years of age with type 1 diabetes receiving a subsidised insulin pump: 2010-11 117 people, 2011-12 178 people, 2012-13 76 people.In 2013-14, the target number of subsided insulin pumps was Met, with 204 people assessed as eligible to receive access to a subsidised insulin pump through the programme.
Quantitative KPI
Percentage of eligible people with diabetes who are able to access clinically appropriate products
2013-14 Target
100%
2013-14 Actual
100%
Result
Met
All eligible applicants were able to access clinically appropriate products in 2013-14.

Assist people with a stoma by providing stoma related products

The Department continued in 2013-14 to support the revised programme pricing and listing framework for the Stoma Appliance Scheme (the Scheme), including listing two new products on the Scheme and making amendments to seven product listings. New and revised listings of stoma products offer a wider choice of subsidised products for people with a stoma. In addition, a review of price premiums as part of a 2012-13 Budget measure was completed and a review of products in Group 9 of the Scheme schedule was commenced.

Quantitative Deliverable
Number of people receiving stoma related products
2013-14 Target
41,750
2013-14 Actual
42,228
Result
Met
Quantitative Deliverable – Number of people receiving stoma The number of people receiving stoma related products: 2010-11 39,023 people, 2011-12 40,142 people.In 2013-14, 42,228 people received stoma related products.
Quantitative KPI
Percentage of eligible people with stomas who are able to access clinically appropriate products
2013-14 Target
100%
2013-14 Actual
100%
Result
Met
Eligible people with stomas were able to access more than 400 clinically appropriate products for the treatment and management of stoma related conditions. All eligible people with stomas were able to receive products.

Improve the quality of life for people with Epidermolysis Bullosa

The Department has continued to provide access to clinically appropriate dressings for people with Epidermolysis Bullosa through the National Epidermolysis Bullosa Dressing Scheme (the EB Scheme). The EB Scheme continues to assist people with Epidermolysis Bullosa by reducing the financial burden associated with purchasing necessary dressings.

Quantitative Deliverable
Number of people with Epidermolysis Bullosa receiving subsidised dressings
2013-14 Target
83
2013-14 Actual
136
Result
Met
Quantitative Deliverable – Number of people with Epidermolysis The number of people with Epidermolysis Bullosa receiving subsidised dressings: 2010-11 71 people, 2011-12 81 people, 2012-13 99 people.The number of people with Epidermolysis Bullosa who are receiving subsidised dressings has significantly increased, in line with changes in 2012-13 to expand eligibility for the EB Scheme to all age groups.

Outcome 2 – Financial Resource Summary

(A) Budget Estimate 1
2013-14
$’000
(B) Actual
2013-14
$’000
Variation
(Column B minus
Column A)
$’000
Programme 2.1: Community Pharmacy and Pharmaceutical Awareness
Administered Expenses
Ordinary Annual Services (Annual Appropriation Bill 1)
367,530
374,606
7,076
Departmental Expenses
Departmental Appropriation2
7,677
7,987
310
Expenses not requiring appropriation in the current year3
365
346
( 19)
Total for Programme 2.1
375,572
382,939
7,367
Programme 2.2: Pharmaceuticals and Pharmaceutical Services
Administered Expenses
Ordinary Annual Services (Annual Appropriation Bill 1)
195,105
194,942
( 163)
Special appropriations
National Health Act 1953 – Pharmaceutical Benefits4
9,259,663
9,119,655
( 140,008)
Departmental Expenses
Departmental Appropriation2
48,498
49,045
547
Expenses not requiring appropriation in the current year3
3,205
2,937
( 268)
Total for Programme 2.2
9,506,471
9,366,579
( 139,892)
Programme 2.3: Targeted Assistance – Pharmaceuticals
Administered Expenses
Ordinary Annual Services (Annual Appropriation Bill 1)
141,504
134,121
( 7,383)
Departmental Expenses
Departmental Appropriation2
2,435
2,261
( 174)
Expenses not requiring appropriation in the current year3
109
100
( 9)
Total for Programme 2.3
144,048
136,482
( 7,566)
Programme 2.4: Targeted Assistance – Aids and Appliances
Administered Expenses
Ordinary Annual Services (Annual Appropriation Bill 1)
1,551
1,500
( 51)
Special appropriations
National Health Act 1953 – Aids and Appliances
302,765
288,128
( 14,637)
Departmental Expenses
Departmental Appropriation2
2,147
2,201
54
Expenses not requiring appropriation in the current year3
102
98
( 4)
Total for Programme 2.4
306,565
291,927
( 14,638)
Outcome 2 Totals by appropriation type
Administered Expenses
Ordinary Annual Services (Annual Appropriation Bill 1)
705,690
705,169
( 521)
Special appropriations
9,562,428
9,407,783
( 154,645)
Departmental Expenses
Departmental Appropriation2
60,757
61,494
737
Expenses not requiring appropriation in the current year3
3,781
3,481
( 300)
Total Expenses for Outcome 2
10,332,656
10,177,927
( 154,729)
Average Staffing Level (Number)
274
261
( 13)

1 Budgeted appropriations taken from the 2014-15 Health Portfolio Budget Statements and re-aligned to the 2013-14 programme group structure.

2 Departmental appropriation combines ‘Ordinary annual services (Appropriation Bill 1)’ and ‘Revenue from independent sources (s31)’.

3 ‘Expenses not requiring appropriation in the budget year’ is made up of depreciation expense, amortisation, make good expense and audit fees. This estimate also includes approved operating losses – please refer to the departmental financial statements for further information. Some reclassifications have been made to the Budget estimates to more accurately reflect the allocation of departmental depreciation by outcome.

4 Revenue is not included in the Budget Estimates, from 2014-15 all revenues will be excluded from PBS expenditure in the Department’s Annual Report. Full details on PBS expenditure is available at www.pbs.gov.au/info/browse/statisitcs#expenditure

In this section